Furthermore, Pirh2 is able to attenuate the nuclear factor-κB (NF-κB) pathway in bortezomib-resistant multiple myeloma cells via ubiquitination of pIKBa and IKKa, the two critical regulators of NF-κB46. This evidence concerns the gene RCHY1 and plasma cell myeloma.